BNGO Bionano Genomics, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.18
P/S
0.14
EV/EBITDA
-0.32
DCF Value
$-119.55
FCF Yield
-474.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.0%
Operating Margin
-114.0%
Net Margin
-109.9%
ROE
-71.4%
ROA
-48.8%
ROIC
-60.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $6.7M | $-8.3M | $— |
| Q4 null | $8.0M | $-7.9M | $— |
| FY null | $28.5M | $-26.4M | $— |
| Q3 null | $7.4M | $-8.5M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$46.50
Target (Median)
$5.00
Target Range
$1.00 - $175.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.62
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.